| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/13/1997 | WO1997009051A1 Analogs for specific oligosaccharide-neuregulin interactions and uses thereof |
| 03/13/1997 | WO1997009042A1 Pharmaceutical formulation |
| 03/13/1997 | WO1997009035A1 Long-lasting composition for rectal administration |
| 03/13/1997 | WO1997009032A1 Utilization of an extract of a non photosynthetic filamentary bacterium and composition containing such extract |
| 03/13/1997 | WO1997008960A1 Antistress agents for aquatic animals |
| 03/13/1997 | WO1996035453A3 Endothelin antagonists and endothelin synthase inhibitors for the prevention and treatment of interine contractility disorders, preeclampsia, atherosclerotic vascular disease, hypertension and or hormone replacement therapy |
| 03/13/1997 | DE19533330A1 Gegen Hautkrebs wirksame topische Zubereitungen Against skin cancer effective topical preparations |
| 03/13/1997 | CA2230968A1 Method of treating insulin resistance |
| 03/13/1997 | CA2230557A1 Interactive molecular conjugates |
| 03/13/1997 | CA2230385A1 Analogs for specific oliogosaccharide-neuregulin interactions and uses thereof |
| 03/13/1997 | CA2228667A1 Antagonists of the oncogenic activity of the protein mdm2, and use thereof in the treatment of cancers |
| 03/12/1997 | EP0761211A1 Sustained release composition |
| 03/12/1997 | EP0761204A1 Use of extracts of filamentous, non photosynthetic bacteria and the composition containing them |
| 03/12/1997 | EP0760864A1 Dna encoding glutamate gated chloride channels |
| 03/12/1997 | EP0760675A1 Compositions comprising dna damaging agents and p53 |
| 03/12/1997 | EP0760667A1 Cancer treatment and metastasis prevention |
| 03/12/1997 | EP0760665A1 COMPOSITION CONTAINING 5HT IA? and 5HT ID? ANTAGONISTS |
| 03/12/1997 | EP0760661A1 Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies |
| 03/12/1997 | EP0760650A1 Antimicrobial oil-in-water emulsions |
| 03/12/1997 | EP0489048B1 Inhibition of tumor growth by blockade of the protein c system |
| 03/12/1997 | EP0409940B1 Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
| 03/12/1997 | CN1145033A Human therapeutic uses of BPI protein products |
| 03/12/1997 | CN1145027A Use of insulin sensitisers for treating renal diseases |
| 03/11/1997 | US5610193 Pharmaceutical composition |
| 03/11/1997 | US5610192 Inhibitors of metazoan parasite proteases |
| 03/11/1997 | US5610184 Method for sustained and extended corneal analgesia |
| 03/11/1997 | US5610173 Formulations for lipophilic compounds |
| 03/11/1997 | US5610134 Treatment of congestive heart failure |
| 03/11/1997 | US5609590 PH-triggered osmotic bursting delivery devices |
| 03/11/1997 | CA2109435C Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals |
| 03/06/1997 | WO1997008310A1 Novel 3' terminal sequence of hepatitis c virus genome and diagnostic and therapeutic uses thereof |
| 03/06/1997 | WO1997008249A1 Acid resistant calcium carbonate composition containing an aluminum salt and uses therefor |
| 03/06/1997 | WO1997008180A1 Method to improve the biological and antiviral activity of protease inhibitors |
| 03/06/1997 | WO1997007821A1 Antipruriginous cosmetic and/or pharmaceutical compositions consisting of one or several light local anaesthetics and one or several astringent substances |
| 03/06/1997 | WO1997007820A1 Remedy for heart diseases |
| 03/06/1997 | WO1997007802A1 Methods and compositions for treating fungal infections in mammals |
| 03/06/1997 | WO1997007801A1 New applications of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-[n-(1,2-benzisothiazolyl-3(2h)one-1,1-dioxide]ethyl |
| 03/06/1997 | WO1997007793A1 Formulations of haloalkylamines and local anaesthetics and methods for the treatment of reflex sympathetic dystrophy (rsd) |
| 03/06/1997 | WO1997007757A1 Bismuth-containing compounds in topical dosage forms |
| 03/06/1997 | WO1997005285A3 Methods and compositions for identifying morphogen analogs |
| 03/06/1997 | DE19531893A1 Juckreizmildernde, kosmetische und/oder pharmazeutische Zusammensetzungen Juckreizmildernde, cosmetic and / or pharmaceutical compositions |
| 03/06/1997 | CA2666298A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 03/06/1997 | CA2230856A1 Methods and compositions for treating fungal infections in mammals |
| 03/06/1997 | CA2230648A1 Formulations of haloalkylamines and local anaesthetics and methods for the treatment of reflex sympathetic dystrophy (rsd) |
| 03/06/1997 | CA2230094A1 Acid resistant calcium carbonate composition containing an aluminum salt and uses therefor |
| 03/06/1997 | CA2203624A1 New applications of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-¬n-(1,2-benzisothiazolyl-3(2h)one-1,1-dioxide¦ethyl |
| 03/06/1997 | CA2203377A1 Method for testing myocarditis or cardiomyopathy |
| 03/05/1997 | EP0760482A2 Method for judging eradication of H. pylori based on rates of changes in the pepsinogen I/II ratio |
| 03/05/1997 | EP0759980A1 Interleukin-6 splice variant |
| 03/05/1997 | EP0759976A1 The isolation and production of catalytic antibodies using phage technology |
| 03/05/1997 | EP0759939A1 Methods and compositions for the dry powder formulation of interferons |
| 03/05/1997 | EP0759783A1 Anti-inflammatory wound healing compositions and methods for preparing and using same |
| 03/05/1997 | EP0759781A1 Method for treating and preventing atherosclerosis |
| 03/05/1997 | EP0759770A1 Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels |
| 03/05/1997 | EP0759754A1 A method of modifying angiotensin receptor activity for treatment of premenstrual syndrome and mediation of pain |
| 03/05/1997 | EP0759752A1 Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
| 03/05/1997 | EP0759750A1 Compositions for treatment of chronic inflammatory diseases |
| 03/05/1997 | CN1144094A Membrane agent drug made of sodium fulvate and/or berberine for curing gynecopathy |
| 03/04/1997 | US5608072 Retroviral protease inhibiting compounds |
| 03/04/1997 | US5607967 Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
| 03/04/1997 | US5607692 Mixture of two lipid vesicle dispersions: first for deep layer treatment has anti- or de-pigmenting agent or tyrosinase inhibitor; second for surface layer treatment has keratolytic, moisturizing or protective agent |
| 02/27/1997 | WO1997007208A1 Nucleic acid molecules encoding peptides having pronociceptive properties |
| 02/27/1997 | WO1997007136A2 Pharmaceutical composition containing inhibitors of interferon-gamma |
| 02/27/1997 | WO1997007135A2 Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof |
| 02/27/1997 | WO1997006818A1 Pharmaceutical compositions for competitively inhibiting the binding of a retrovirus to the ifn-receptor and means for diagnosis of an hiv infection |
| 02/27/1997 | WO1997006813A1 Mucosal preparation containing physiologically active peptide |
| 02/27/1997 | WO1997006807A2 Contraceptive combined preparation, kits containing the same and contraceptive method using this combined preparation |
| 02/27/1997 | WO1997006806A1 Use of prostane derivatives and the combination thereof with antibiotics in the treatment of bacterial infections |
| 02/27/1997 | WO1997006804A1 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c |
| 02/27/1997 | WO1997006792A1 Potentiation of serotonin response |
| 02/27/1997 | WO1997006791A1 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS |
| 02/27/1997 | WO1997006786A1 Oral fast-dissolving compositions for dopamine agonists |
| 02/27/1997 | WO1996040885A3 β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION |
| 02/27/1997 | CA2229557A1 Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof |
| 02/27/1997 | CA2228765A1 Pharmaceutical compositions for competitively inhibiting the binding of a retrovirus to the ifn-receptor and means for diagnosis of an hiv infection |
| 02/27/1997 | CA2228036A1 Use of prostane derivatives and the combination thereof with antibiotics in the treatment of bacterial infections |
| 02/26/1997 | EP0759299A1 Potentiation of serotonin response |
| 02/26/1997 | EP0758900A1 Method for reduction of headache pain |
| 02/26/1997 | EP0758899A1 Permeabilizer peptides for increasing blood-ocular barrier permeability |
| 02/26/1997 | EP0758894A1 Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |
| 02/26/1997 | CN1143909A Antitussive composition containing antitussive and benzydamine |
| 02/26/1997 | CN1143500A Use of 1 alpha, 24-dihydroxy vitamin D2 |
| 02/26/1997 | CN1034104C Preparation method for tumor vaccine |
| 02/25/1997 | US5606043 Methods for the diagnosis of glaucoma |
| 02/25/1997 | US5605930 Compositions and methods for treating and preventing pathologies including cancer |
| 02/25/1997 | US5605929 Methods and compositions for inhibiting 5α-reductase activity |
| 02/25/1997 | US5605927 Treatment of skin diseases using ginkgolide PAF antagonists |
| 02/25/1997 | US5605911 Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
| 02/25/1997 | US5605902 5-HT2 receptor antagonist compositions useful in treating venous conditions |
| 02/25/1997 | US5605696 Drug loaded polymeric material and method of manufacture |
| 02/25/1997 | CA2085135C Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| 02/20/1997 | WO1997006242A1 Recombinant c-proteinase and processes, methods and uses thereof |
| 02/20/1997 | WO1997005902A1 Medicinal composition |
| 02/20/1997 | WO1997005895A1 Treatment of ocular inflammatory conditions with interleukin-10 |
| 02/20/1997 | WO1997005888A1 Food product and its manufacturing method |
| 02/20/1997 | WO1997005876A1 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases |
| 02/20/1997 | WO1997005873A2 Use of fluconazole for inhibiting the growth of cancers |
| 02/20/1997 | WO1997005870A2 Use of griseofulvin for inhibiting the growth of cancers |
| 02/20/1997 | WO1997005864A2 Use of l-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs |
| 02/20/1997 | WO1997005862A2 Use of basic amino acids and derivatives for lowering ceramide levels |